Helix BioPharma Corp Signs Collaboration Agreement With Promab Biotechnologies To Co-Develop CAR-T For Hematological Malignancies
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the completion of the collaboration agreement with ProMab Biotechnologies, Inc. (“ProMab”) to develop novel antibody and chimeric antigen receptor T-cell therapy (“CAR-T”) for particular hematological malignancies (i.e. multiple myeloma).
The Company had previously announced the signing of a binding letter of intent (“LOI”) with ProMab to develop CAR-T for various hematological malignancies and solid tumors. Today the Company announced the signing of the first scientific collaboration to co-develop a cell-based therapy for Multiple Myeloma. The Multiple Myeloma co-development program will aim to complete all necessary work with the objective of filing for a first-in-human study by early 2019. Under the collaboration agreement, Helix retains commercial rights for this CAR-T in Canada and Europe and is currently in the process of reviewing what expansion criteria may be required at its European operations in Poland to facilitate commercialization.
In the meantime, Helix’s core team continues to prioritize the Company’s DOS47 drug development program, particularly its clinical L-DOS47 program and its pre-clinical V-DOS47 pre-clinical program.